all to at you for for third Volition XXXX quarter time thank call. for interest Volition's would you joining you, us. Scott and like everyone key thank Thank earnings conference taking this I in again an
the on Vanston, to Financial myself join Chief call me addition and today. David our In Scott Officer
on on It quarter optionality balance key the us. financial. delighted our a this exciting is we of quarter. I time to had made that I'm our numerous We with ways showing excellent focus this strengthened technology. like highlights strong would in progress Initially have very sheet our for indeed two platform fronts, have many being
deal we with equity closed investor. a a long $X most existing financing million term and importantly Firstly
Secondly, to-date additional local non-diluted of approximately non-dilutive of funding meaning the agencies that have $XXX,XXX of we in a in Belgium. we in excess from government number from million secured received funding Walloon regional $X.X
October in company. cash $XXX,XXX exercised in outstanding additional an providing the Additionally certain to were warrants
So excluding and cash totaled September cash October, million ones as $XX.X December added year. is compared extra these our XX XX, equivalents to million at $XX.X last of
to research the efforts first to quarter. these burn to expansion million per cash products average our slightly of market approximately bring Given rate has our $X.X increased
to throughout remain expect We steady XXXX. this
cash position $X prices of cash of the able that by which non-diluted of our in that months exercised could secure revenue $X company. approximate additional are aggregate and exercised from any balance Our the in $XX.X expire and next to in we range that could outstanding exercise further We be a XX sheet warrants plus kit the funding additional if great above the our an sales research with to the million our strengthened per provide believe position. to share within puts
the our developments third during quarter. Now let's review
from a now step success the critical This much would production assays time very By that and that ready. help is albeit laboratories and in massive same This critical analytically key year product clinical was team a I be so of today. which for and to the to they is analytical This will to has needed consuming outline in the used for wide work will range ensure very can mountain level been the worldwide. clinical our and products their areas reproduced that trials for of much will this like dedicated [ph] dedicated validity assays Throughout grade be Our grade in I of development run variable bearing that lab. clinics is work future team our completed now in mean development from clinical some fruit. usable anywhere of of effort. focus is very successfully past becoming be of be XXXX during our advancing and development I our that thank in trials our in can the validated a work process. any large
Our clinical integrate assays grade used product follows our trials a two for we and be of into the prong the development can in discovery pronged first approach that publications. all improvements
these even quarter artificial months this as in on grade XX significant example exciting believe ago. improvements was initial something as For utilizing little impossible These assays. discovery prostate data work released cancer nucleosomes include we
trials We the other number in next to diseases we grade as of with assays months more discovery these and a different expect range in provide yet updates few underway of a have complete kinds trial. [ph] and
lab and prong then a used well in grade large assays final product run further and second kit shelf these our work assays involves grade their The needed for long them Belgium. very team in developing taking This for gone in robust any product be in and trials. indeed worldwide. discovery also our including has all These research components can be validation a to with in training to life
and it fair say proven time consuming be has the However robustness to is the a to of on undertaking. development this assays massive
assay but discovery worked colorectal delayed requires a group the previously regards to to absolutely in nucleosomics the from have in intellectual individual unique assay magnitude product minimum XXX sometimes It’s knowledge work over trials. view believe we the we product achievements for we work to property that company has has of I has trials as most of clinical what to done this a with are communicated Given much XX to each different product amount it diagnostic samples. of experiments are the particular strong stage future of when XX to-date samples of then developing is stage of that of product work This currently our the approach large completed our first describe useful cancer. be all the and the Broader milestones is base and undertaken study clinical for a correct and a assays. had each is in valuable asset scratch. strong foundation field from we wide but After building work clinical of and are in and our we range an this extremely the nucleosomes opportunities. have taking
and Circulating with assays entrants prudent a have investigation regular how advancing rerunning it for our now the on with Now is believe that in we preanalytical has work quality cancer drug products, run to but disease studies robust collected DNA far Liquid late testing progressing basis. assays how our tumor samples stage a a assays. final finalized ready very run to are. before given is assays story of reproducible biopsy assays we they with This samples factor adjusting DNA sequencing so clinical come, in used area before that the product process again success been have for the involving different these for study large of we're tumor clinical have studies selection. in new from retrospective has been and circulating and various and new of a rapidly our is of been the number ways complicating stage our
cancer for being early However success to-date stage circulating DNA tumor a detection. has not
central alone early aware that using in details a tumor [indiscernible] the the that the path [Indiscernible] an magnitude of DNA their multiple blood detection tumor a poster screening detection patients tumor order to needing pricing as cancer in solving an draw tumor other incorporated is important integrate brief forward markets be this. remain cost. challenging more found circulating sequencing biological and is from interesting lower DNA cell-free recent decreases A of for us this be DNA as as and mutations large as technical issues. very a in might means which of in others such of mutated extremely focus with source. published finding and their to on piece such DNA We encountered cancer believe make approaches difficulties stage other nucleosomes analysis reasons a alone. summary this Volition development inflammatory and a levels proponent This the likely we is is DNA hear that markets markers multiple cell-free extremely credible like space in opinion without of circulating that You significant uneconomic from this to circulating early blood best renewed expect the ours. highly We base on using and in will for will doing practical, cases analysis stage work with cancer are from these many other such the
ensure have been test of put always the approaches have best orthogonal to we integration open into a our this We possible test. to and lot of get resources to area
to and assays. as our Nu to be add for same run on that criteria platform the assays cost platform assays able should Q low new orthogonal Our to Q are be our
identified inflammatory cancer we in very have in study In Belgium. biopsy men two from cost be discovery already we found preliminary these useful prostate the involving for a announced We've of detection addition some cancer. in referred to prostate markets low results which
Just was of Q PSA these and markers new in detection our the with two inflammatory as rate assays. a reminder XX% of both
inflammatory new greatly the markers the with With helping discrimination.
test other range patent they now We as we we accurate model. our to intellectual wide announce for protection low these looking fit most to applying as that to of portfolio. for also are could markets inflammatory with at the novel ensure add blood long of routine possible test property also markers are dozens have We innovative cost
using and modifications nucleosomes scientific partner but can announce and In also these of product of is coming this first as a several month of revenue we will product fair kits this the to groups world. in today quarters to this the trickle to and around are in first scientific range been sold further a we nucleosomes. have of our confirmation generate detection. that mass had data that quarter a approach I We exclusive the gives spec and for recent experiments this number further these a our already find I with Active this research our to Motif. interest platform applied isolated These expect cancer have histone to our in in for distributed be is like in global say spec it cancer launch community. for line believe these our possible an the which our in mass Another results use kit trial have additional last sales found We to be exciting our just ahead stage growing our the independent involves the ELISA of validation call research announce and to results. strong prostate early is breakthrough delighted same the at from water our products that we us our research Germany our product. the corporate was distribution lab most quarter blood also circulating that kits, offerings spec success we then to in of story ELISA preliminary would by agreement further data sold last mass
mentioned high grade Volition's of the specificity trial PSA market which large improvement very potential I opportunity. panel the this XX%. are our score inflammatory markers earlier in Gleason prostate the to significant demonstrates larger cancers This PSA treatment and identified and a assays results if two technology be As according alone XX% is the breadth clinical further at validated to including platform just Such just of idea require would method. of excellent a identified XX% five that
forward pathway look months. working and now development how coming products secure the the announcing are larger on We to trials for to in prostate
collection study to and reporting these We prestigious with our University quarter also we the of this results months. sample completion in announced in very England look of the Oxford, recently coming forward the endometriosis
prostate, breadth we the become Q have This first development and with XXXX ovarian patients cancer XX and the clinical is of gastric few. our our of the Nu very cancers. happy our that further work Bonn, underway. addition the and most the technology test colorectal In is that our Germany study. of through important assays they are of patient to it we hope but cohort will already already we report begun of cancer to name study University direct collected prevalent to notably XX cancers, show the to as In This grade We on a have pancreatic, aim has trial cancer Nu all Q help and analyzing confirm BonnXX run available. by our includes lung, this these and
trials range data a for preliminary platform commercial to assays study other experts these extremely of see different XXXX. in another our a application report We that of in expect is will licensing expansion our our veterinary of anniversary work more cancers. this to in in aim BonnXX XXth that cancers. and can our The cancer nucleosomes announced product be study of how be to from various we become recently results for through concept completed the interesting A& We have announce and/or technology our similar individual the the organization we I in meeting quarter this assays indeed can to are study demonstrated ways Mission at Q University. M It Technology We results and exciting new through Belgium that diagnostics. Yet dogs similarly of horses. Nu the at detected presented with proof Texas the
from areas broad have the delivery on delighted were trial University. technology product Asian aim of and further the any key Such to of and veterinary the with progress on the so market, commercialisation we're to launch announce initial of to really the the highlight a much We U.S. find experienced that business to foster possible Taiwan we to company's helps be these a recruitment perspective to necessary about strategy months. diagnostics in Our one would in success. focus relationships collaborations process delighted our strengths of signing remains with impact [indiscernible] human and a application believe Nu National this announce consultant Further very market. trials Nathan clinical significant we over our working in application and this in firmly Q an and this developments coming collaboration commencement platform two key the the
and in principal trial for the be colorectal asymptomatic in a including to of Asia subjects colorectal rights regulatory validate symptomatic With of cancer marketing, would and up first platform Volition's press Chiu, Professor world globally studies the Nu by XX,XXXX and and investigator diagnosis Professor trial and in colorectal include with cohorts further for the leaders. Nu of visited and These that already a European the region our large to reminder release last way scale will platform its R&D renowned was our collaborating U.S. commitment part multi-center Q multi-country, existing Q a [ph] studies subject Asia. a lead proprietary are for institutions in Belgium, night. commercialize demonstrates detection Asian Han-Mo of facility study key recently to the to and patients. video multi-ethnic Chiu Pacific addition cancer Volition's cohorts, These our second test which XXXX purposes conducted cancer XXXX opinion and featured XX,XXX screening approximately subject cohorts are been the
the good ways serum both use circulating throughout in broad as in has in members serum, as market. with it different important? the the In and in these interviews insight that what preparing and scientific rigor videos areas meets discussed feedback To high two organization and assays which why interviews to at watch of with bring provide well this will features publicly calls who in the video scientific trials would in urge help okayed of plasma plasma. to work members this our companies on that Chiu with mean drive visit for happy video run Once is number of work is in advanced to it the a first serum twice lot as as turn input board fact to facility our out provide on the well Board, a invaluable very year quarter was international expertise and SAB I of of also for second our person included of a helps they addition provided can technology Professor is is we announce members important? our I for advice a level with we our a and number of DNA today large common assays to us team a them. our Why optimized been multi-disciplinary Scientific very the and research least plasma. our released well live. to like SAB counsel very I'm also a this Advisory Our of solely This with team. tumor plasma SAB thank and trials and into
remainder Going interested both on triage the made forward I to milestones we have front and anyone bring XXXX assays will pre-analytical and the once do line for watching analysis to the to finalized which in products the we work upcoming aim and many what the completed. colorectal report all and the was videos both and for policy into so the levels in-depth be for our plasma. provide a now recommend serum we to cancer XXXX. data assays have further and starting for life of company can I screening preclinical as We to
trials process Our are U.S. and large also Asian the in colorectal of collection.
exciting trials to hard extremely pathways the large our early Following prostate months also a of development in coming working and commercialisation to forward products to data we announcing look in secure are a cancer. prostate
to we just are developing however our will expect a come which the expect the we Q to of next revenue as platform sales of To kit from we products [ph] add-in the further We from next generate products clear to commence and researchers be from year. more year. and of sales expect add to to up through Motif Nu number recent ramp a products much we rather clinical validation having significant Active companies our large to as sales of greatly think would than continue revenue this sales research we range of
We our before strategy large in our receiving expect involving data into to dog to three U.S. EDRN U.S. most prevalent with to study colorectal mid-sized cancers trials a to from add conjunction this broaden and study the also as product also develop available. data population further becomes horses We hope in us veterinaries give well.
colorectal building lastly the addition validity concept on to the made other study but make earlier. quarter have I've here underway work before trials report we with of further difference the and many study much the mentioned a completed. the not like to revolutionize so to taking team critical cancer has including our the our endometriosis our is intellectual And say the like it for many calls be several in of to an our to countries prostate very strengthen data people such market if it we to visionary this to aim been in significant the I'd convey a massive cancer proof on again, said diagnostic. portfolio In and that patents importantly plan BonnXX U.S. we also and thank work is technology and progress from fronts. as property in of very but cancer would key platform by but I our it's on sincerely amount to it to easy cancer we are This goal successful thing It additional
We of we and in us week be many get about the excited early healthcare meeting. San love January Like are coming will you would a optimistic to for so with in please months. in touch and Francisco see extremely book we you to
brighter over the the Volition. forward one hard we to together along coming Thank Operator? We company look quarters. to and to all. where the hope create cancer our rest case work proud thus future We the whole same our the the I look day and and achieved you for can of results a come and sharing are of studies sentence. in months what Board extremely of far every the have accomplishments with future indeed and holds forward
